Precision Neuroscience Corp: Business Overview, Financials & Competitive Analysis
Precision Neuroscience Corp scores 8/10 on the AskCyborg Cyborg Score (Strong). Well-capitalized BCI innovator leveraging minimally-invasive technology to address $4.5B+ addressable market opportunity with significant first-mover advantages in clinical validation. Precision Neuroscience demonstrates strong technical execution with proprietary minimally-invasive BCI architecture, substantial capital backing ($183M raised), and emerging clinical partnerships. The BCI market growth trajectory (projected to expand from $2.3B.
What is Precision Neuroscience Corp's industry? Precision Neuroscience Corp (precisionneuro.io) operates in Medical Devices. AskCyborg classifies Precision Neuroscience Corp under Medical Devices in its company registry.
Precision Neuroscience offers a platform for next generation brain-computer interface technology, targeting treatment of neurological conditions including spinal cord injuries, stroke, paralysis, and epilepsy. The com...
Cyborg Score thesis
Well-capitalized BCI innovator leveraging minimally-invasive technology to address $4.5B+ addressable market opportunity with...
Read the full analyst-debate transcript →Get the Latest Precision Neuroscience Corp Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePrecision Neuroscience Corp Overview
Pro stress-test →Precision Neuroscience offers a platform for next generation brain-computer interface technology, targeting treatment of neurological conditions including spinal cord injuries, stroke, paralysis, and epilepsy. The company is building a minimally invasive brain–computer interface with a thin-film microelectrode array that conforms to the brain surface without penetrating the brain tissue.
Strategic Profile
Pro stress-test →Founded in 2021 by Michael Mager, Benjamin Rapoport and Mark Hettick, the company is well-positioned in the growing neurotech market. In December 2024, Precision Neuroscience raised $102M in Series C funding, bringing total capitalization to $183M across six rounds, with ~117 employees as of January 2026.
Competitive Landscape
Pro stress-test →Precision Neuroscience competes in the emerging BCI market against companies like Synchron (endovascular BCI), Neuralink (invasive electrode approach), and academic/clinical research programs at institutions such as Stanford and MIT. Its minimally-invasive, surface-conforming electrode design differentiates from both invasive and non-invasive competing approaches, targeting faster clinical adoption pathways.
Industry Context
Precision Neuroscience Corp operates in Medical Devices.
Key facts
Founded: 2021 · Headquarters: New York, US · Employees: 117